Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AML19 in adults with acute myeloid leukaemia or high-risk myelodysplastic syndrome
ISRCTN78449203Phase 3Completed
- Sponsor
- Cardiff University
- Start
- Jan 2015
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, open-label trial of gemtuzumab ozogamicin, midostaurin, daunorubicin and cytarabine in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) (4 arms), sponsored by Cardiff University. Primary endpoint: Overall survival. Started Jan 2015; status: completed.
02
Drugs
gemtuzumab ozogamicinmidostaurindaunorubicincytarabine
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on ISRCTN78449203.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN78449203.